MD Anderson
Radiation Oncology
Ann Klopp, MD, PhD is a Professor, Director of Radiation Oncology Gynecological Services, and Center Medical Director, COVID Vaccine Clinic at The University of Texas MD Anderson Cancer Center. Dr. Klopp’s research and clinical practice focus on the use of advanced radiation techniques to reduce toxicity and improve outcomes for women with gynecologic cancers receiving radiation therapy. She leads research protocols to improve outcomes for women with cervical cancer, including investigating the impact of real-time MRI guidance to guide the position of brachytherapy applicators and evaluating a combination of HPV directed vaccine with radiation therapy. In addition, she is a physician-scientist investigating the effects of the tumor microenvironment on the biology of gynecologic cancers, including the tumor and gut microbiome. Her research is funded by the Emerson Collective and the MD Anderson Moonshot program. She also serves as the co-chair of the Corpus Committee at NRG Oncology and the President of the American Brachytherapy Society.

Presenter of 1 Presentation

RANDOMIZED TRIAL OF PELVIC RADIATION WITH AND WITHOUT CONCURRENT CISPLATIN IN PATIENTS WITH A PELVIC ONLY RECURRENCE OF ENDOMETRIAL CANCER

Session Type
Plenary Session
Date
09/29/2022
Session Time
04:55 PM - 05:55 PM
Room
Hall 501
Session Icon
Live
Lecture Time
04:57 PM - 05:05 PM
Onsite or Pre-Recorded
Onsite

Abstract

Objectives

The pelvis is a common site of recurrence for patients with endometrial cancers. A randomized trial was conducted to compare progression-free survival in patients treated with radiation therapy alone as compared to radiation therapy with concurrent cisplatin-based chemotherapy.

Methods

165 Patients were accrued between February 2009 and August 2020. Women with recurrent endometrial carcinoma limited to the pelvis were eligible. The median time for follow up for vital status was 60 months.

Results

Most patients had grade 1 or 2 endometroid endometrial cancer (81%) and most recurrences were vaginal (86%). Radiation therapy was delivered to the pelvis with 3D or IMRT techniques followed by HDR or LDR interstitial or intracavitary brachytherapy. Chemotherapy was delivered with weekly cisplatin. Grade 4 or higher acute adverse event were reported in 8 participants in the chemotherapy and radiation arm as compared to 1 treated with radiation only. 68% of patients treated with radiation therapy were alive and progression-free as compared to 59.8% of those that received chemotherapy and radiation. Overall, patients treated with weekly cisplatin had a lower rate of PFS as compared to patients treated with radiation alone (stratified HR=1.40, 95% CI: 0.82-2.39, p=0.8919).

Conclusions

Results of this randomized trial suggest that the addition of chemotherapy does not improve, and may worsen, outcomes for patients treated with definitive radiation therapy for recurrent endometrial cancer. Those with low grade and vaginal apex recurrences may be best treated with radiation therapy alone.

Hide